154825-93-1 Usage
Description
4-(4-Hydroxy-1-butynl)-A,A-dimethylbenzeneacetic Acid, Methyl Ester is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its yellow-greenish oil appearance and plays a significant role in the development of medications, particularly in the pharmaceutical industry.
Uses
Used in Pharmaceutical Industry:
4-(4-Hydroxy-1-butynl)-A,A-dimethylbenzeneacetic Acid, Methyl Ester is used as an intermediate in the synthesis of 4-(4-Chloro-1-oxobutyl)-α,α-dimethylbenzeneacetic Acid Methyl Ester (C374930), which is a key component in the production of fexofenadine (F322490). Fexofenadine is an antihistamine drug used to treat symptoms of seasonal allergies, such as sneezing, itching, watery eyes, and runny nose. The compound's role in the synthesis process is essential for the development of effective allergy medications.
Check Digit Verification of cas no
The CAS Registry Mumber 154825-93-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,4,8,2 and 5 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 154825-93:
(8*1)+(7*5)+(6*4)+(5*8)+(4*2)+(3*5)+(2*9)+(1*3)=151
151 % 10 = 1
So 154825-93-1 is a valid CAS Registry Number.
InChI:InChI=1/C15H18O3/c1-15(2,14(17)18-3)13-9-7-12(8-10-13)6-4-5-11-16/h7-10,16H,5,11H2,1-3H3
154825-93-1Relevant articles and documents
Repurposing the antihistamine terfenadine for antimicrobial activity against staphylococcus aureus
Perlmutter, Jessamyn I.,Forbes, Lauren T.,Krysan, Damian J.,Ebsworth-Mojica, Katherine,Colquhoun, Jennifer M.,Wang, Jenna L.,Dunman, Paul M.,Flaherty, Daniel P.
supporting information, p. 8540 - 8562 (2014/12/11)
Staphylococcus aureus is a rapidly growing health threat in the U.S., with resistance to several commonly prescribed treatments. A high-throughput screen identified the antihistamine terfenadine to possess, previously unreported, antimicrobial activity against S. aureus and other Gram-positive bacteria. In an effort to repurpose this drug, structure-activity relationship studies yielded 84 terfenadine-based analogues with several modifications providing increased activity versus S. aureus and other bacterial pathogens, including Mycobacterium tuberculosis. Mechanism of action studies revealed these compounds to exert their antibacterial effects, at least in part, through inhibition of the bacterial type II topoisomerases. This scaffold suffers from hERG liabilities which were not remedied through this round of optimization; however, given the overall improvement in activity of the set, terfenadine-based analogues provide a novel structural class of antimicrobial compounds with potential for further characterization as part of the continuing process to meet the current need for new antibiotics.
